About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- BMI categories: overweight 25-29.9, obesity >=30, class III obesity >=40; waist circumference refines cardiometabolic risk
- Assess obesity complications: diabetes, hypertension, dyslipidemia, sleep apnea, fatty liver disease, osteoarthritis, GERD, depression, infertility
- Foundation: intensive multicomponent lifestyle intervention with nutrition, physical activity, and behavioral strategies
- Anti-obesity pharmacotherapy is appropriate for BMI >=30 or >=27 with weight-related comorbidity
- Metabolic/bariatric surgery is considered for BMI >=40 or >=35 with comorbidity; newer guidance supports broader use in selected patients
Overview
Obesity is a chronic disease driven by genetic, biologic, environmental, behavioral, medication, sleep, socioeconomic, and endocrine factors. It should be evaluated with BMI, waist circumference, weight trajectory, medications, eating patterns, sleep, mental health, and complications. Management is not merely advice to eat less; it requires structured intervention, longitudinal support, anti-obesity pharmacotherapy when indicated, and metabolic surgery for eligible patients.
Epidemiology
Obesity affects a large proportion of US adults and is associated with type 2 diabetes, ASCVD, hypertension, dyslipidemia, obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, chronic kidney disease, infertility, pregnancy complications, and several cancers. Weight stigma reduces care quality and adherence, so clinical framing should be respectful, complication-focused, and practical.
Clinical Features
Symptoms
Often presents for weight management, diabetes risk, or comorbidity care
Snoring, witnessed apnea, daytime sleepiness suggesting obstructive sleep apnea
Exertional dyspnea, joint pain, GERD symptoms
Irregular menses, infertility, hirsutism suggesting PCOS
Rapid weight gain with proximal weakness, bruising, or purple striae suggesting Cushing syndrome
Signs
Elevated BMI and/or increased waist circumference
Hypertension, acanthosis nigricans, skin tags
Hepatomegaly suggesting fatty liver disease
Osteoarthritis signs or reduced mobility
Cushingoid features are red flags for secondary endocrine obesity
Investigations
First-line
BMI and waist circumferenceClassify body size and visceral adiposity risk; interpret with clinical context
Blood pressure, HbA1c/fasting glucose, lipid panelScreen common cardiometabolic complications
ALT/ASTEvaluate fatty liver risk when clinically indicated
Second-line
Sleep apnea screeningSTOP-Bang or sleep study if snoring, witnessed apneas, daytime sleepiness, resistant hypertension
Medication reviewIdentify weight-promoting drugs: insulin, sulfonylureas, antipsychotics, antidepressants, glucocorticoids, beta-blockers, gabapentinoids
TSHIf symptoms/signs of hypothyroidism; routine broad endocrine testing is not needed without clues
Specialist
Bariatric surgery evaluationFor eligible patients or those with severe obesity-related complications
Endocrine testingIf Cushing syndrome, hypothalamic obesity, hypogonadism, PCOS, or genetic obesity syndrome suspected
1
Lifestyle and behavioral intervention
- Intensive, multicomponent behavioral intervention with frequent contact is more effective than brief advice alone
- Individualize nutrition strategy: calorie deficit, high protein/fiber, reduced ultra-processed foods, culturally appropriate plan
- Physical activity target: at least 150 min/week moderate aerobic activity, progressing when possible; add resistance training
- Address sleep, stress, binge eating, depression, food insecurity, and weight-promoting medications
2
Pharmacotherapy
- Consider for BMI >=30 or BMI >=27 with weight-related comorbidity
- Modern options include GLP-1 receptor agonists and dual GIP/GLP-1 agonists where approved/available; monitor GI adverse effects, gallbladder disease, pancreatitis risk, and contraindications
- Older agents include orlistat, phentermine/topiramate, naltrexone/bupropion, and short-term sympathomimetics in selected patients
- Continue medication if clinically meaningful weight loss and tolerability; discontinue or change if ineffective
3
Metabolic/bariatric surgery
- Consider for BMI >=40 or BMI >=35 with significant obesity-related comorbidity; selected lower BMI thresholds may apply in diabetes and current surgical society guidance
- Procedures include sleeve gastrectomy and Roux-en-Y gastric bypass
- Requires lifelong nutritional monitoring and supplementation
4
Comorbidity-focused care
- Treat diabetes, hypertension, dyslipidemia, fatty liver disease, sleep apnea, osteoarthritis, GERD, and reproductive complications
- Set realistic goals: 5-10% weight loss improves many metabolic parameters; larger losses may be needed for sleep apnea or NASH improvement
Complications
- Type 2 diabetes and metabolic syndrome: Insulin resistance increases cardiometabolic disease risk
- ASCVD and hypertension: Risk mediated by BP, lipids, inflammation, diabetes, and sleep apnea
- Obstructive sleep apnea and obesity hypoventilation: Can cause pulmonary hypertension and right heart strain
- Fatty liver disease: May progress to steatohepatitis, cirrhosis, and hepatocellular carcinoma
- Nutritional deficiency after bariatric surgery: Iron, B12, folate, calcium, vitamin D, thiamine deficiencies require surveillance
USMLE Step 2 CK Exam Tips
- 1Obesity evaluation is complication-focused: diabetes, BP, lipids, sleep apnea, fatty liver, medications
- 2Routine Cushing testing is not indicated unless specific features exist: proximal weakness, easy bruising, wide purple striae
- 3Anti-obesity medications: BMI >=30 or >=27 with comorbidity is the classic threshold
- 4Bariatric surgery thresholds commonly tested: BMI >=40 or >=35 with comorbidity
- 5Orlistat adverse effects: oily stools and fat-soluble vitamin malabsorption
- 6Naltrexone/bupropion is avoided in seizure disorder and chronic opioid use
- 7Phentermine/topiramate is teratogenic — pregnancy prevention is essential
- 8After bariatric surgery, vomiting/confusion/ataxia = thiamine deficiency until proven otherwise
practicetest your knowledge on obesityApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — endocrine and beyond.
open q-bank